Skip to main content
Sarat Chandarlapaty, MD, Oncology, New York, NY, Memorial Sloan Kettering Cancer Center

SaratChandarlapatyMDPhD

Oncology • New York, NY

Hematologic Oncology

Associate Member, Human Oncology and Pathogenesis Program, MSKCC

Request Appointment

Overview of Dr. Chandarlapaty

Dr. Sarat Chandarlapaty is an oncologist in New York, NY and is affiliated with Memorial Sloan-Kettering Cancer Center. He received his medical degree from Wake Forest School of Medicine and has been in practice 15 years. He specializes in hematologic oncology.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2009
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2002 - 2004
  • Wake Forest School of Medicine of Wake Forest Baptist Medical Center
    Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2002

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • NJ State Medical License
    NJ State Medical License 2019 - 2025
  • NY State Medical License
    NY State Medical License 2003 - 2025

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Article Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer  
    Sarat Chandarlapaty, Alison M Schram, David M Hyman, David B Solit, ScienceDirect
  • Neratinib Is Effective in Breast Tumors Bearing Both Amplification and Mutation of ERBB2 (HER2)  
    José Baselga, Kyriakos P. Papadopoulos, Sarat Chandarlapaty, David B. Solit, Science Magazine
  • Immunohistochemical Analysis of Estrogen Receptor in Breast Cancer with ESR1 Mutations Detected by Hybrid Capture-Based Next-Generation Sequencing  
    Marcia Edelweiss, Edi Brogi, Dara S Ross, Fumiko Konno, Sarat Chandarlapaty, Nature

Lectures

  • Liquid Biopsies: Are They Ready for Prime Time in Breast Cancer? 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

  • MSK’s Research Roundup at AACR 2022: Targeted Therapy for Lung Cancer, Using Statins with a Breast Cancer Drug, and Diagnosing Blood Cancer
    MSK’s Research Roundup at AACR 2022: Targeted Therapy for Lung Cancer, Using Statins with a Breast Cancer Drug, and Diagnosing Blood CancerApril 11th, 2022
  • SERDs Represent the Next Generation of ER-Targeting Therapy in Breast Cancer
    SERDs Represent the Next Generation of ER-Targeting Therapy in Breast CancerJuly 31st, 2021
  • Early Amcenestrant Data Featured at ASCO Support Its Potential to Become a New Endocrine Backbone Therapy for ER+/HER2- Breast Cancer
    Early Amcenestrant Data Featured at ASCO Support Its Potential to Become a New Endocrine Backbone Therapy for ER+/HER2- Breast CancerMay 19th, 2021
  • Join now to see all

Grant Support

  • Biologic And Therapeutic Implications Of AKT Activation In HER2+ Breast CancerNational Cancer Institute2009–2011

Professional Memberships

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Cofinity PPO
    Empire BCBS HMO
    Empire BCBS PPO
    GHI PPO
    Great West PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    QualCare HMO
    QualCare PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Sarat Chandarlapaty, Dr. Sarat Chandarlapaty, MD, Dr. S Chandarlapaty